Prophylactic, or preventive, treatment with deucrictibant significantly reduced the rate of swelling attacks among adults with hereditary angioedema (HAE) in a Phase 2 clinical trial. “These study results, together with the compelling data from our on-demand program, further strengthens our confidence that deucrictibant can become the preferred option…
In a clinical trial, most people with hereditary angioedema (HAE) given on-demand treatment with PHVS416, an immediate-release capsule formulation of deucrictibant, saw swelling attacks begin to resolve within half an hour of taking the medication. That’s according to new data presented in a poster, titled “…
The European Commission (EC) has granted orphan drug designation to NTLA-2002, an investigational gene-editing therapy that Intellia Therapeutics is developing for hereditary angioedema (HAE). The designation is given to therapies with the potential to improve medical care for people with serious conditions that affect up to five of…
Even with long-term preventive treatment, many people with hereditary angioedema still sometimes have swelling attacks that require on-demand treatment, a review study finds.
The design of an ongoing Phase 3 clinical trial testing sebetralstat as an on-demand oral treatment for swelling attacks in hereditary angioedema (HAE) was based on feedback from patients and data from a previous Phase 2 trial. The approach was described in the study “Evaluation…
Up to one year of treatment with Takhzyro (lanadelumab) significantly reduced rates of swelling attacks and improved quality of life for children with hereditary angioedema (HAE) ages 2 through 11, according to results from the Phase 3 SPRING clinical trial. Results from the trial helped support the U.S.
New treatments for hereditary angioedema (HAE) have been life-changing for people in the U.K., but more and better efforts are needed to educate emergency workers on providing care, according to a new study. The survey study found that HAE patients in Great Britain still frequently have upsetting experiences when…
Treatment with Orladeyo (berotralstat) effectively prevented swelling and improved life quality for three people with hereditary angioedema (HAE) with no known disease-causing mutations. “Our results provide the first evidence that [Orladeyo] can be an effective therapy in patients with HAE [who do not have any known mutations],” scientists…
Preventive treatment with Takhzyro (lanadelumab) reduced the rate of swelling attacks and improved life quality for Japanese patients with hereditary angioedema (HAE) in a Phase 3 clinical trial. These findings helped to support Takhzyro’s approval in Japan last year for the prevention of swelling attacks in HAE…
The U.S. Food and Drug Administration (FDA) has approved a new generic version of Firazyr (icatibant injection) for hereditary angioedema (HAE), Aurobindo Pharma announced in a press release. Like the brand-name medication, the new generic is indicated to treat acute swelling attacks of HAE in adults 18…
Get regular updates to your inbox.